Simpler Grants.gov #HT942526BCRPTBCCA

Transformative Breast Cancer Research Consortium Funding Opportunity

The Defense Health Agency, through the Congressionally Directed Medical Research Programs (CDMRP), is soliciting applications for the FY26 Breast Cancer Research Program Transformative Breast Cancer Consortium Award (TBCCA): - Government Buyer: - Defense Health Agency (DHA), Defense Health Agency Research and Development (DHA R&D), Defense Health Agency Contracting Activity (DHACA) - US Army Medical Research Acquisition Activity (USAMRAA) - Award Details: - Up to $35 million total funding for a single consortium - Maximum period of performance is four years - Funded with FY26 funds; performance period extends until funds expire - Program Requirements: - Supports a multidisciplinary, multi-institutional research consortium - Consortium must include 4-5 project teams, each led by a Principal Investigator (PI), with a Consortium Director - Each project team must include at least one breast cancer consumer advocate - Focus on innovative, high-impact research addressing major breast cancer challenges - Requires annual In-Progress Review meetings and biannual workshops - Data sharing and integration across teams is required - Eligibility: - Open to domestic and foreign, public and private, for-profit and nonprofit organizations - No cost sharing or matching required - No specific OEMs or commercial vendors are named, as this is a research funding opportunity rather than a procurement of products or equipment

Description

The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium's collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. This funding mechanism allows for up to five Principal Investigators (PIs) including the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team.

View original listing